- Home
- XRN vs ALT Comparison
XRN vs ALT Comparison
Compare XRN & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XRN | ALT |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | United States | United States |
| Employees | 30 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 525.8M | 421.5M |
| IPO Year | 2016 | 2005 |
Fundamental Metrics
Financial Performance| Metric | XRN | ALT |
|---|---|---|
| Price | $37.57 | $2.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 74.4K | ★ 3.9M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 8.56% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $4.50 | N/A |
| Revenue Next Year | $3.83 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $29.05 | $2.56 |
| 52 Week High | $38.65 | $6.44 |
Technical Indicators
Market Signals| Indicator | XRN | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 55.31 | 41.51 |
| Support Level | $34.68 | $2.72 |
| Resistance Level | $38.23 | $3.09 |
| Average True Range (ATR) | 0.96 | 0.13 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 70.11 | 6.27 |
Price Performance
Historical ComparisonAbout XRN Chiron Real Estate Inc. Common Stock
Chiron Real Estate Inc is a real estate investment trust focused on investing and actively managing critical healthcare infrastructure. Its portfolio includes Spectrum-Dumfries, Slippery Rock MOB, Gainesville Eye Center, Aurora Sports Health, and many Others. Geographically, the company has it's concentration in a small number of states, including Texas, Florida, Ohio, Arizona, Pennsylvania, and Illinois.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.